Lawrence Harris

Dr. Lawrence Harris

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2021 in eLife
Verified
Journal Article
Open access
MSMona Seifert
Mona Seifert
SBSubhas C Bera
Subhas C Bera
PNPauline van Nies
Pauline van Nies
RKRobert N Kirchdoerfer
Robert N Kirchdoerfer
ASAshleigh Shannon
Ashleigh Shannon
DDDavid Dulin
David Dulin
The absence of ‘shovel-ready’ anti-coronavirus drugs during vaccine development has exceedingly worsened the SARS-CoV-2 pandemic. Furthermore, new vaccine-resistant variants and coronavirus outbreaks may occur in the near future, and we must be ready to face this possibility. However, efficient antiviral drugs are still lacking to this day, due to our poor understanding of the mode of incorporation and mechanism of action of nucleotides analogs that target the coronavirus polymerase to impair its essential activity. Here, we characterize the impact of remdesivir (RDV, the only FDA-approved anti-coronavirus drug) and other nucleotide analogs (NAs) on RNA synthesis by the coronavirus polymerase using a high-throughput, single-molecule, magnetic-tweezers platform. We reveal that the location of the modification in the ribose or in the base dictates the catalytic pathway(s) used for its incorporation. We show that RDV incorporation does not terminate viral RNA synthesis, but leads the polymerase into backtrack as far as 30 nt, which may appear as termination in traditional ensemble assays. SARS-CoV-2 is able to evade the endogenously synthesized product of the viperin antiviral protein, ddhCTP, though the polymerase incorporates this NA well. This experimental paradigm is essential to the discovery and development of therapeutics targeting viral polymerases.

5 July 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
TPTruc V. Pham
Truc V. Pham
AMAndrew Murkin
Andrew Murkin
MMMargaret M. Moynihan
Margaret M. Moynihan
LHLawrence Harris
Lawrence Harris
PTPeter C. Tyler
Peter C. Tyler
TMThomas D. Meek
Thomas D. Meek
Significance: Tuberculosis, caused byMycobacterium tuberculosis(Mtb) bacteria, is the most prevalent infectious disease, affecting one-third of the global population, especially in developing countries. First-line therapies to treat this disease are losing efficacy due to the emergence of drug resistance. Accordingly, new therapeutic agents of novel mechanisms of action remain an urgent medical need. The isocitrate lyases (ICL1 and ICL2) comprise metabolically essential enzymes ofMtb, are absent in mammals, and thereby provide therapeutically important drug targets for tuberculosis. Here, we describe the first example of a mechanism-based inactivator of ICL1 and ICL2 that could provide a starting point for the development of new drugs to treat tuberculosis.

29 December 2010 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
LHLawrence Harris
Lawrence Harris
SMSimon P. H. Mee
Simon P. H. Mee
RFRichard H. Furneaux
Richard H. Furneaux
GGGraeme J. Gainsford
Graeme J. Gainsford
ALAndreas Luxenburger
Andreas Luxenburger

1 April 2011 in Tetrahedron Letters
Verified
Journal Article
Closed access
PDPhilip J. Davis
Philip J. Davis
LHLawrence Harris
Lawrence Harris
AKAman Karim
Aman Karim
ATAmber L. Thompson
Amber L. Thompson
MGMartin Gilpin
Martin Gilpin
CTClaire Thompson
Claire Thompson

26 November 2012 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
GTGaël Tran
Gaël Tran
RMRobin Meier
Robin Meier
LHLawrence Harris
Lawrence Harris
DBDuncan L. Browne
Duncan L. Browne
SLSteven V. Ley
Steven V. Ley

20 June 2017 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
JMJuliet Macharia
Juliet Macharia
VWVictor Wambua
Victor Wambua
YHYun Hong
Yun Hong
LHLawrence Harris
Lawrence Harris
JHJennifer S. Hirschi
Jennifer S. Hirschi
MVMathew J. Vetticatt
Mathew J. Vetticatt